EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis

Noha Abdelgawad iD, Sean Wasserman, Mahmoud Tareq Abdelwahab, Angharad Davis, Cari Stek, Lubbe Wiesner iD, John Black, Graeme Meintjes, Robert J Wilkinson, Paolo Denti iD

The Journal of Infectious Diseases · 12.04.2024 · 229 (4) · 1200-1208

DOI: 10.1093/infdis/jiad413 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 22.09.2023. Verfasst von Noha Abdelgawad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa. Hauptthemen laut MEDLINE: Rifampin, Tuberculosis, Meningeal. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Wellcome Trust, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linezolid is evaluated in novel treatment regimens for tuberculous meningitis (TBM). Linezolid pharmacokinetics have not been characterized in this population, particularly in cerebrospinal fluid (CSF), as well as, following its co-administration with high-dose rifampicin. We aimed to characterize linezolid plasma and CSF pharmacokinetics in adults with TBM.

Methods

In the LASER-TBM pharmacokinetic substudy, the intervention groups received high-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, which was then reduced to 600 mg/day. Plasma sampling was done on day 3 (intensive) and day 28 (sparse). A lumbar CSF sample was obtained on both visits.

Results

Thirty participants contributed 247 plasma and 28 CSF observations. Their median age and weight were 40 years (range, 27–56) and 58 kg (range, 30–96). Plasma pharmacokinetics was described by a 1-compartment model with first-order absorption and saturable elimination. Maximal clearance was 7.25 L/h, and the Michaelis-Menten constant was 27.2 mg/L. Rifampicin cotreatment duration did not affect linezolid pharmacokinetics. CSF-plasma partitioning correlated with CSF total protein up to 1.2 g/L, where the partition coefficient reached a maximal value of 37%. The plasma-CSF equilibration half-life was ∼3.5 hours.

Conclusions

Linezolid was readily detected in CSF despite high-dose rifampicin coadministration. These findings support continued clinical evaluation of linezolid plus high-dose rifampicin for the treatment of TBM in adults. Clinical Trials Registration. ClinicalTrials.gov (NCT03927313).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinTuberculosis, MeningealAdultHumansCerebrospinal FluidLinezolidMiddle Aged

Stichwörter der Autor:innen

cerebrospinal fluidlinezolidmodeling and simulationpopulation pharmacokineticstuberculosis meningitis

Substanzen

LinezolidRifampin

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
  • Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
  • Institute for Infection and Immunity, St George's University of London, United Kingdom.
  • The Francis Crick Institute, London, United Kingdom.
  • Faculty of Life Sciences, University College London, United Kingdom.
  • Department of Medicine, Walter Sisulu University, Mthatha, South Africa.

ORCID-Profile: Noha Abdelgawad, Lubbe Wiesner, Paolo Denti

Förderung

  • NIAID NIH HHS
  • Wellcome Trust
  • NIH HHS
  • NIMH NIH HHS
  • FIC NIH HHS
  • Cancer Research UK
  • National Institutes of Health
  • Fogarty International Center of the National Institutes of Health

Zitieren

APA

Abdelgawad, N., Wasserman, S., Abdelwahab, M. T., Davis, A., Stek, C., Wiesner, L., Black, J., Meintjes, G., Wilkinson, R. J., & Denti, P. (2024). Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis. The Journal of Infectious Diseases, 229(4), 1200-1208. https://doi.org/10.1093/infdis/jiad413

Vancouver

Abdelgawad N, Wasserman S, Abdelwahab MT, Davis A, Stek C, Wiesner L, et al. Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis. The Journal of Infectious Diseases. 2024;229(4):1200-1208. doi:10.1093/infdis/jiad413

BibTeX
@article{Abdelgawad2024,
  author = {Abdelgawad, Noha and Wasserman, Sean and Abdelwahab, Mahmoud Tareq and Davis, Angharad and Stek, Cari and Wiesner, Lubbe and Black, John and Meintjes, Graeme and Wilkinson, Robert J and Denti, Paolo},
  title = {Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {229},
  number = {4},
  pages = {1200--1208},
  doi = {10.1093/infdis/jiad413}
}
Kostenlos starten →